Skip to main content
PEPTARA LABS
Get Started
Peptara Labs Thymosin Alpha-1 10mg vial
Thymus peptide

Thymosin Alpha-1 for Sale

Published by · Updated · How we research and check our pages

Thymus Peptide, Studied in Immune Research

Thymosin alpha-1 from Peptara Labs (peptaralabs.io) is a 10mg research-grade vial for $85 USD, the Thymosin Alpha-1 Black Friday price: 45% off the regular $155, and it ships as soon as stock arrives. Its batch certificate of analysis is pending, so no purity figure is claimed yet. It is sold for research use only.

Black Friday price, 45% off, ends November 30

$85 USDWas $155 USD

Black Friday price, 45% off, ends November 30

Flat $35 tracked shipping10mg per vial

Ships as soon as stock arrives

1vial

$85 USD

Was $155

$85.00 per vialWas $155.00Black Friday price

Add 2 more, unlock 50%

Vials of any product count together in your cart: 1 to 2 vials 45% off, 3 to 4 vials 50% off, 5 to 9 vials 55% off, 10 or more 60% off. No code is added on top.

Batch certificate pending
Peptara Labs Thymosin Alpha-1 10mg vial

Shipping, delivery and certificate status

Shipping
Flat $35, tracked worldwide to supported markets
Delivery
Ships as soon as stock arrives · After dispatch: 5 to 10 business days
Included
Vial · Batch certificate pending · Order support on WhatsApp

Buyer facts

What do you get when you buy thymosin alpha-1 from Peptara Labs?

One sealed 10mg vial of lyophilized thymosin alpha-1 powder. The order contains this vial only.

DetailThymosin alpha-1Where to check it
CompoundThymosin alpha-1, TA1, Tα1; thymalfasinIdentity checks below
Vial10mg, sealed lyophilized powderVial listing
Price$85 USD, the Thymosin Alpha-1 Black Friday price: 45% off the regular $155Order panel above
AvailabilityPre-order. Ships as soon as stock arrives. Delivery follows dispatch.Shipping note above
CertificateBatch certificate pendingCertificate status
UseLaboratory research onlyResearch-use label

Your order includes the vial. Batch certificate pending. Delivery details are confirmed with your order. Order support is available on WhatsApp.

Research vial
Batch certificate pending
Delivery information with your order
Order support

Share or cite this page

Add as preferred on Google

Sources: PubChem, CID 16130571.

Before you buy

What should you check before you buy thymosin alpha-1?

Thymosin alpha-1 is a 28 amino acid peptide. PubChem lists formula C129H215N33O55 and molecular weight 3108.3 g/mol for thymalfasin. The similar name TB-500 describes a different molecule, a short fragment of thymosin beta-4.

The research literature describes solid-phase synthesis for the synthetic peptide used in clinical research. That manufacturing method does not verify a vial. A batch certificate should check identity by mass spectrometry and purity by HPLC. This batch certificate is pending, so no purity figure is claimed.

The peptide purity guide explains the checks, and the certificates page shows current status.

Sources: PubChem, CID 16130571; Li et al., 2010, Peptides, PMID 20699109; FDA safety-risk listing, content current April 22, 2026.

The short answer

What is thymosin alpha-1?

Thymosin alpha-1 is a peptide of 28 amino acids first described from calf thymus tissue in 1977. It is also written TA1 or Tα1. PubChem lists thymalfasin and Zadaxin among its names.

A 2009 review reported approvals in over 35 countries for hepatitis B and C and as an immune stimulant and adjuvant. That is an approval-history fact from 2009. This Peptara Labs vial is sold for research use only.

Sources: Li et al., 2010, Peptides, PMID 20699109; PubChem, CID 16130571; Goldstein and Goldstein, 2009, Expert Opin Biol Ther, PMID 19392576.

The science

How does thymosin alpha-1 act on immune cells?

Research centers on dendritic cells, which help the immune system recognize targets, and T cells, which help organize its response. Reviews describe Toll-like receptors on two kinds of dendritic cells and changes in cytokines, the signals immune cells send to each other.

Mouse and cell studies linked dendritic-cell maturation to MyD88 and NF-kB, parts of the cell's signaling machinery. That work examined antifungal Th1 responses. Other lab studies examined T-cell and antibody responses and whether thymosin alpha-1 blocked steroid-related death of developing thymus cells. These findings describe research pathways; they do not establish a general immunity claim.

Toll-like receptors

Studies examined receptors that help immune cells sense targets.

Dendritic-cell maturation

Mouse and cell work measured changes in the cells that present targets to T cells.

T-cell signals

Research examined T-cell responses, cytokines and antibody responses.

Sources: King and Tuthill, 2016, Vitam Horm, PMID 27450734; Romani et al., 2004, Blood, PMID 14982877; Li et al., 2010, Peptides, PMID 20699109.

Applications

What has thymosin alpha-1 been studied in?

Hepatitis B and C

Reviews describe clinical research and the peptide's dated approval history.

Sepsis

Two large trials examined 28-day deaths and safety outcomes.

Vaccine response

Researchers examined antibody and immune responses alongside vaccines.

Immune aging

A review describes immune changes with age as a research area.

COVID-19 research

A 2020 review discussed it as a proposed area, rather than an established result.

Sources: Goldstein and Goldstein, 2009, Expert Opin Biol Ther, PMID 19392576; King and Tuthill, 2016, Vitam Horm, PMID 27450734; Dominari et al., 2020, World J Virol, PMID 33362999; Wu et al., 2013, Crit Care, PMID 23327199; Wu et al., 2025, BMJ, PMID 39814420.

Comparison

Thymosin alpha-1 vs thymosin beta-4 (TB-500) and LL-37

Thymosin alpha-1 and thymosin beta-4 are different molecules. TB-500 is a short fragment of thymosin beta-4, rather than another name for thymosin alpha-1. LL-37 has a separate identity and research record.

PeptideIdentityResearch distinction
Thymosin alpha-128 amino acid peptideImmune-cell signaling and clinical immune research
Thymosin beta-4 fragment, TB-500The LKKTETQ fragment listed by the FDAA separate fragment; the shared thymosin name does not make it TA1
LL-37A separate peptide on the FDA safety-risk pageIts evidence should be read separately from thymosin alpha-1

The dedicated TB-500 and LL-37 pages describe their own records. None of these names proves that two compounds have the same action.

Sources: Li et al., 2010, Peptides, PMID 20699109; King and Tuthill, 2016, Vitam Horm, PMID 27450734; FDA safety-risk listing, content current April 22, 2026.

Evidence

What did the thymosin alpha-1 trials find?

Immune-cell research

Model: Dendritic cells and mouse fungal-infection models.

Reported: Researchers examined cell maturation, IL-12 and Th1 signals.

ETASS sepsis trial

Model: 361 adults at six hospitals in China.

Reported: A mortality signal did not reach the usual statistical threshold.

TESTS sepsis trial

Model: 1,106 enrolled adults at 22 centers in China.

Reported: The larger blinded trial found no clear evidence of lower 28-day deaths.

FDA safety-risk listing

Model: Compounding substances nominated and then withdrawn.

Reported: The regulator notes immune-reaction risk and inadequate safety information.

The two sepsis trials side by side

TrialYearPeopleDesign28-day deaths, TA1 vs controlAuthors' conclusion
ETASS2013361Randomized, single-blind; six hospitals in China26.0% vs 35.0%; unstratified P 0.062A possible signal in a targeted group; no serious event tied to the study compound
TESTS20251,106 enrolled; 1,089 analyzedDouble-blind, placebo-controlled phase 3; 22 centers in China23.4% vs 24.1%; hazard ratio 0.99; P 0.93No clear evidence of lower 28-day deaths; no safety outcome differed

The larger, better blinded trial did not confirm the smaller trial's signal. ETASS recorded no serious adverse event tied to the study compound. TESTS found no difference in safety outcomes between groups. Those trial observations do not establish that every research product is safe.

The FDA lists thymosin alpha-1 among compounding substances nominated and then withdrawn. It notes immune-reaction risk and inadequate safety information. Research findings, a dated medicine approval and this pending batch certificate are separate facts.

Sources: Romani et al., 2004, Blood, PMID 14982877; Wu et al., 2013, Crit Care, PMID 23327199; Wu et al., 2025, BMJ, PMID 39814420; FDA safety-risk listing, content current April 22, 2026. The TESTS trial disclosed SciClone support.

What is not known

What is still unknown about thymosin alpha-1?

The cited studies give no half-life figure. The two sepsis trials ran in China and reached different conclusions as trial size and blinding changed. Their findings do not settle every immune-research question.

A ClinicalTrials.gov search for thymosin alpha 1 returned 66 records on October 7, 2026. The count records listed studies. It does not establish efficacy or approval.

Sources: Wu et al., 2013, Crit Care, PMID 23327199; Wu et al., 2025, BMJ, PMID 39814420; ClinicalTrials.gov search, October 7, 2026.

Research timeline

How the thymosin alpha-1 record was built

Research timeline

How the thymosin alpha-1 record was built

1977: first description

Researchers first described the 28 amino acid peptide from calf thymus tissue.

2004: immune-cell studies

Cell and mouse work examined dendritic-cell maturation and Toll-like receptor pathways.

2009: approval-history review

A review reported approvals in over 35 countries at that time.

2013: ETASS trial

A 361-person sepsis trial found a mortality signal that did not reach the usual significance threshold.

2025: TESTS trial

The larger blinded trial found no clear evidence of lower 28-day mortality.

2026: FDA safety-risk listing

The FDA listed thymosin alpha-1 among compounding nominations that were withdrawn and described safety concerns.

Your Kit

What's Included

Thymosin Alpha-1 research vial

$85 USD Was $155 USD

Flat $35 tracked shipping · Ships as soon as stock arrives · Batch certificate pending · Order support on WhatsApp

Black Friday price, 45% off, ends November 30

Order Thymosin Alpha-1

Thymosin Alpha-1 10mg Vial

10mg per vial

Batch certificate

Batch certificate pending

Delivery

Ships as soon as stock arrives · After dispatch: 5 to 10 business days

Order support

Contact our team about your order or batch certificate.

Your order includes the vial. Batch certificate pending. Delivery details are confirmed with your order. Order support is available on WhatsApp.

Research vial
Batch certificate pending
Delivery information with your order
Order support

Your Research Order

Thymosin Alpha-1 research vial, batch certificate status, delivery and order support.

Batch certificate

Batch certificate pending

Delivery

Ships as soon as stock arrives · After dispatch: 5 to 10 business days

Order support

Contact our team about your order or batch certificate.

Order Thymosin Alpha-1

Questions

Buying thymosin alpha-1: FAQ

How much is thymosin alpha-1 at Peptara Labs?

A 10mg research vial is $85 USD, the Thymosin Alpha-1 Black Friday price: 45% off the regular $155. Ships as soon as stock arrives. Delivery follows dispatch. It is sold for research use only.

Where can I buy thymosin alpha-1 online?

Peptara Labs lists thymosin alpha-1 on this page as a 10mg research vial. Its batch certificate is pending, so no purity figure is claimed yet.

Is a batch certificate available for this thymosin alpha-1 vial?

The batch certificate of analysis is pending. No purity figure, test date or batch number is claimed before a certificate is released.

Thymosin alpha-1 research FAQ

What is thymosin alpha-1?

Thymosin alpha-1 is a 28 amino acid peptide first described from calf thymus in 1977. Thymalfasin is the name of a synthetic version used as a medicine in some countries. This vial is sold as research material.

Is thymosin alpha-1 the same as TB-500?

No. TB-500 is a short fragment of thymosin beta-4, a different protein. The two share the word thymosin, rather than a structure or a research record.

What did large trials of thymosin alpha-1 find?

In the 2025 TESTS trial, 1,106 adults with sepsis were enrolled and 1,089 analyzed. Deaths at 28 days were 23.4% with thymosin alpha-1 and 24.1% with placebo. The authors found no clear evidence of lower mortality.

Is thymosin alpha-1 an approved medicine?

A 2009 review reported approvals in over 35 countries for hepatitis B and C and as an immune stimulant and adjuvant. The review describes approval history in 2009. It does not establish current approval in every country. This research vial is not that medicine.

How does thymosin alpha-1 affect immune cells in research?

Cell and mouse studies examined Toll-like receptors, dendritic-cell maturation and T-cell responses. Those measurements describe how the cells responded in the studies.

What side effects did thymosin alpha-1 trials record?

ETASS reported no serious adverse event tied to the study compound. TESTS found no difference in safety outcomes between groups. The FDA separately notes immune-reaction risk and inadequate safety information for the compounding substance.

Sources: Li et al., 2010, Peptides, PMID 20699109; PubChem, CID 16130571; Goldstein and Goldstein, 2009, Expert Opin Biol Ther, PMID 19392576; King and Tuthill, 2016, Vitam Horm, PMID 27450734; Romani et al., 2004, Blood, PMID 14982877; Wu et al., 2013, Crit Care, PMID 23327199; Wu et al., 2025, BMJ, PMID 39814420; FDA safety-risk listing, content current April 22, 2026.

Order Thymosin Alpha-1, 10mg research vial

Order Thymosin Alpha-1. Ships as soon as stock arrives · After dispatch: 5 to 10 business days. Order support on WhatsApp.

Order Now

Batch certificate pending · Ships as soon as stock arrives · Order support on WhatsApp

Chat with us